Indurashmi Mayakrishnan, MD
Neurology · Sherman, TXNPI 1205023702
Payments from drug & device makers
Across 108 payments — averaging $62.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$2K
- Inspire Medical Systems, Inc.$1K
- Biotronik NRO, Inc.$401
- Jazz Pharmaceuticals Inc.$228
- Harmony Biosciences LLC$226
- Eisai Inc.$206
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$1502%
- Travel & lodging$1,17718%
- Food & beverage$5,25979%
- Education$1132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 16 | $2,456 |
| Inspire Medical Systems, Inc. | 10 | $1,153 |
| Biotronik NRO, Inc. | 1 | $401 |
| Jazz Pharmaceuticals Inc. | 5 | $228 |
| Harmony Biosciences LLC | 3 | $226 |
| Eisai Inc. | 5 | $206 |
| AstraZeneca | 3 | $196 |
| AbbVie | 5 | $196 |
| UCB, Inc. | 3 | $168 |
| Teva Pharmaceuticals USA, Inc. | 3 | $141 |
| Lilly USA, LLC | 6 | $134 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $130 |
| SK Life Science, Inc. | 5 | $130 |
| Pfizer | 6 | $117 |
| Sumitomo Pharma America, Inc. | 6 | $117 |
| Argenx US, Inc. | 4 | $100 |
| Lundbeck LLC | 3 | $83 |
| Boston Scientific | 1 | $79 |
| Neurocrine Biosciences, Inc. | 3 | $71 |
| Neurelis, Inc. | 3 | $60 |
| Ensodata, Inc. | 1 | $47 |
| Catalyst Pharmaceuticals, Inc. | 2 | $44 |
| Acadia Pharmaceuticals Inc | 1 | $36 |
| Scilex Pharmaceuticals Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Noctrix Health, Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Adamas Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,698 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 46 | $690,640 |
| SolirisEculizumab | 13 | $681,794 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 93 | $663,736 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $238,338 |
| NuplazidPimavanserin Tartrate | 24 | $106,212 |
| IngrezzaValbenazine Tosylate | 11 | $87,330 |
| QuliptaAtogepant | 36 | $62,584 |
| BriviactBrivaracetam | 35 | $51,310 |
| RytaryCarbidopa/Levodopa | 20 | $40,446 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $36,304 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 17 | $23,012 |
| UbrelvyUbrogepant | 14 | $21,359 |
| Emgality PenGalcanezumab-Gnlm | 20 | $21,194 |
| Lacosamide | 54 | $18,962 |
| Oxtellar XrOxcarbazepine | 18 | $15,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $196 | $681,79413 claims |
| Acadia Pharmaceuticals IncNuplazid | $36 | $106,21224 claims |
| AbbVieQulipta, Ubrelvy, Namzaric | $196 | $93,51167 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $71 | $87,33011 claims |
| UCB, Inc.Briviact | $168 | $51,31035 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $14 | $46,94281 claims |
| Eisai Inc.Dayvigo | $206 | $3,79412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.
Other neurology in Sherman
- Bharathy SundaramSherman$7.2M
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
- Benjamin GreenbergDallas$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.